Your browser doesn't support javascript.
loading
Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers.
Pachi, Ioanna; Koros, Christos; Simitsi, Athina M; Papadimitriou, Dimitra; Bougea, Anastasia; Prentakis, Andreas; Papagiannakis, Nikolaos; Bozi, Maria; Antonelou, Roubina; Angelopoulou, Efthalia; Beratis, Ion; Stamelou, Maria; Trapali, Xenia Geronicola; Papageorgiou, Sokratis G; Stefanis, Leonidas.
Afiliação
  • Pachi I; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Koros C; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Simitsi AM; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Papadimitriou D; Neurology Clinic, Henry Dunan Hospital, Athens, Greece.
  • Bougea A; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Prentakis A; Nuclear Medicine Unit, Attikon Hospital, Athens, Greece.
  • Papagiannakis N; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Bozi M; 2nd Department of Neurology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Antonelou R; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Angelopoulou E; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Beratis I; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Stamelou M; Parkinson's Disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece; School of Medicine, European University of Cyprus, Nicosia, Cyprus.
  • Trapali XG; Nuclear Medicine Unit, Attikon Hospital, Athens, Greece.
  • Papageorgiou SG; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Stefanis L; 1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: lstefanis@bioacademy.gr.
Parkinsonism Relat Disord ; 91: 1-8, 2021 10.
Article em En | MEDLINE | ID: mdl-34425330
ABSTRACT

INTRODUCTION:

Higher prevalence of motor and non-motor features has been observed in non-manifesting mutation carriers of Parkinson's Disease (PD) compared to Healthy Controls (HC). The aim was to detect the differences between GBA and LRRK2 mutation carriers without PD and HC on neuropsychiatric symptoms.

METHODS:

This is a cross-sectional retrospective study of non-manifesting GBA and LRRK2 mutation carriers and HC enrolled into Parkinson's Progression Markers Initiative (PPMI). Data extracted from the PPMI database contained demographics and performance in MoCA scale and MDS-UPDRS scale part 1A (neuropsychiatric symptoms). All six features were treated as both continuous (MDS-UPDRS individual scores) and categorical variables (MDS-UPDRS individual score>0 and MDS-UPDRS individual score = 0). Logistic regression analyses were applied to evaluate the association between mutation carrying status and neuropsychiatric symptoms.

RESULTS:

In this study, the neuropsychiatric evaluation was performed in 285 GBA non-manifesting carriers, 369 LRRK2 non-manifesting carriers and 195 HC. We found that GBA non-manifesting mutation carriers were 2.6 times more likely to present apathy compared to HC, even after adjustment for covariates (adjusted OR = 2.6, 95% CI = 1.1-6.3, p = 0.031). The higher percentage of apathy for LRRK2 carriers compared to HC was marginally non-significant. GBA carriers were 1.5 times more likely to develop features of anxiety compared to LRRK2 carriers (adjusted OR = 1.5, 95% CI = 1.1-2.2, p = 0.015). Other neuropsychiatric symptoms, such as psychotic or depressive manifestations, did not differ between groups.

CONCLUSION:

Symptoms of apathy could be present in the prediagnostic period of non-manifesting mutation carriers, especially, GBA. Longitudinal data, including detailed neuropsychiatric evaluation and neuroimaging, would be essential to further investigate the pathophysiological basis of this finding.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Apatia / Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina / Glucosilceramidase / Heterozigoto Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Apatia / Serina-Treonina Proteína Quinase-2 com Repetições Ricas em Leucina / Glucosilceramidase / Heterozigoto Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article